当前位置:
X-MOL 学术
›
Int. J. Clin. Pract.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients
International Journal of Clinical Practice ( IF 2.2 ) Pub Date : 2021-09-15 , DOI: 10.1111/ijcp.14877 Hongxue Meng 1 , Lan Huang 2 , Jiahui Wang 2 , Yingxu Zhou 2 , Meng Wang 2 , Zhaoyang Yang 2 , Xuan Hong 2
International Journal of Clinical Practice ( IF 2.2 ) Pub Date : 2021-09-15 , DOI: 10.1111/ijcp.14877 Hongxue Meng 1 , Lan Huang 2 , Jiahui Wang 2 , Yingxu Zhou 2 , Meng Wang 2 , Zhaoyang Yang 2 , Xuan Hong 2
Affiliation
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used to treat patients with EGFR-mutated non-small cell lung cancers (NSCLCs). The association between the clinical outcomes of patients on first-line EGFR-TKIs and the efficacy of osimertinib as second-line treatment has not been previously assessed. This is our topic here.
中文翻译:
服用第一代 EGFR-TKI 患者的临床结果可预测奥希替尼对 EGFR T790M 突变 NSCLC 患者的益处
表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI) 广泛用于治疗EGFR突变的非小细胞肺癌 (NSCLC) 患者。先前尚未评估一线 EGFR-TKI 患者的临床结果与奥希替尼作为二线治疗的疗效之间的关联。这是我们这里的主题。
更新日期:2021-09-15
中文翻译:
服用第一代 EGFR-TKI 患者的临床结果可预测奥希替尼对 EGFR T790M 突变 NSCLC 患者的益处
表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI) 广泛用于治疗EGFR突变的非小细胞肺癌 (NSCLC) 患者。先前尚未评估一线 EGFR-TKI 患者的临床结果与奥希替尼作为二线治疗的疗效之间的关联。这是我们这里的主题。